Brief: Phio Pharmaceuticals Presents Study Outline Of Its First Clinical Trial With Ph-762 For Advanced Melanoma At The 2022 Asco Annual Meeting
06/06/2022 19:16
June 6 (Reuters) - Phio Pharmaceuticals Corp PHIO.O :
* PHIO PHARMACEUTICALS PRESENTS STUDY OUTLINE OF ITS FIRST
CLINICAL TRIAL WITH PH-762 FOR ADVANCED MELANOMA AT THE 2022
ASCO ANNUAL MEETING
Source text for Eikon: ID:nPn7115z3a
Further company coverage: PHIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing